Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Leiss JK, Lyden JT, Mathews R, Sitzman KL, Vanderpuije A, Mav D, Kendra MA, Klein C, Humphrey CJ. Blood exposure incidence rates from the North Carolina study of home care and hospice nurses. Am J Ind Med. 2009 Feb 1;52(2):99-104.
Lanes SF, Rothman KJ, Dreyer NA, Soden K. Mortality among workers exposed to glycerol polyglicidyl ether. Am J Ind Med. 1994 May;25(5):689-96. doi: 10.1002/ajim.4700250508
Lanes SF, Rothman KJ, Soden KJ, Amsel J, Dreyer NA. Mortality among synthetic-fiber workers exposed to glycerol polyglycidyl ether. Am J Ind Med. 1994 Jan 1;25(5):689-96.